{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:59:16Z","timestamp":1790834356553,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl. Int."],"abstract":"<jats:p>This retrospective observational study investigated the frequency of post-transplant leukopenia and neutropenia (PTLN) and its association with cytomegalovirus (CMV) infections, clinical outcomes, and healthcare resource utilization (HCRU) in kidney transplant recipients (KTRs) in Finland. Clinical and HCRU data were collected from electronic medical records and national registries for the years 2013\u20132022. Clinical outcomes were assessed during the first 18 months, and cost-related outcomes were evaluated up to 4 years post-transplant. The cohort included 966 KTRs, with the following donor\/recipient CMV serostatus distribution: R+ 706 (73.1%), D+\/R\u2500 200 (20.7%), and D\u2500\/R\u2500 60 (6.2%). At 12 months, PTLN occurred in 224 (31.7%) R+, 103 (51.5%) D+\/R\u2500, and 6 (10.0%) D\u2500\/R\u2500 recipients (p &amp;lt; 0.001). Valganciclovir prophylaxis was started in 28.0% of R+ and 95.0% of D+\/R\u2500 patients. CMV DNAemia occurred in 357 (50.6%) R+ and 106 (53.0%) D+\/R\u2500 recipients, with median time to CMV DNAemia of 66 days (IQI: 48\u2013110) in R+ and 239 days (IQI: 175\u2013323) in D+\/R\u2500 recipients (p &amp;lt; 0.001). PTLN and D+\/R\u2500 serostatus were associated with higher HCRU and increased healthcare costs. In conclusion, PTLN was more common in CMV D+\/R\u2500 KTRs and both D+\/R\u2500 serostatus and PTLN were linked to greater healthcare utilization and cost burden.<\/jats:p>","DOI":"10.3389\/ti.2026.16893","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:10:11Z","timestamp":1790831411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The frequency and timing of leukopenia and CMV infections in kidney transplant recipients in Finland \u2013 a retrospective observational study"],"prefix":"10.3389","volume":"39","author":[{"given":"Ilkka","family":"Helanter\u00e4","sequence":"first","affiliation":[{"name":"Transplantation and Liver Surgery, Helsinki University Hospital, University of Helsinki","place":["Helsinki, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Helsinki University Hospital, Abdominal Center, Nephrology","place":["Helsinki, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essi","family":"Havula","sequence":"additional","affiliation":[{"name":"Medaffcon Oy","place":["Espoo, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuli","family":"Tuominen","sequence":"additional","affiliation":[{"name":"Medaffcon Oy","place":["Espoo, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hakam\u00e4ki","sequence":"additional","affiliation":[{"name":"Kidney Center, Turku University Hospital and University of Turku","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapio","family":"Hellman","sequence":"additional","affiliation":[{"name":"Kidney Center, Turku University Hospital and University of Turku","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tampere University Hospital","place":["Tampere, Finland"]},{"name":"Faculty of Medicine and Health Technology, Tampere University","place":["Tampere, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Korhonen","sequence":"additional","affiliation":[{"name":"MSD Finland","place":["Espoo, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e14000","DOI":"10.1111\/tid.14000","article-title":"Burden of neutropenia and leukopenia among adult kidney transplant recipients: a systematic literature review of observational studies","volume":"25","author":"Raval","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.transproceed.2021.04.011","article-title":"Risk factors and management of leukopenia after kidney transplantation: a single-center experience","volume":"53","author":"Henningsen","year":"2021","journal-title":"Transplant Proc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e14583","DOI":"10.1111\/ctr.14583","article-title":"Outcomes among CMV\u2010mismatched and highly sensitized kidney transplants recipients who develop neutropenia","volume":"36","author":"Brar","year":"2022","journal-title":"Clin Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/TP.0b013e31821c1e70","article-title":"Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States renal data system","volume":"92","author":"Hurst","year":"2011","journal-title":"Transplantation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/tp.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/15269248211024614","article-title":"Predictors and complications of post kidney transplant leukopenia","volume":"31","author":"Vinson","year":"2021","journal-title":"Prog Transpl"},{"key":"B7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/tid.12247","article-title":"Current characteristics and outcome of cytomegalovirus infections after kidney transplantation","volume":"16","author":"Helanter\u00e4","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1432-2277.2006.00364.x","article-title":"Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival","volume":"19","author":"Helanter\u00e4","year":"2006","journal-title":"Transpl Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1034\/j.1600-6143.2002.20907.x","article-title":"The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients","volume":"2","author":"Sagedal","year":"2002","journal-title":"Am J Transpl"},{"key":"B10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12235","DOI":"10.3389\/ti.2024.12235","article-title":"Infection-related hospitalizations after simultaneous pancreas-kidney transplantation compared to kidney transplantation alone","volume":"37","author":"Grasberger","year":"2024","journal-title":"Transpl Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/ije\/29.3.587","article-title":"Human cytomegalovirus seroprevalence in three socioeconomically different urban areas during the first trimester: a population-based cohort study","volume":"29","author":"Mustakangas","year":"2000","journal-title":"Int J Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3109\/23744235.2015.1123290","article-title":"Decrease in seroprevalence for herpesviruses among pregnant women in Finland: cross-sectional study of three time points 1992, 2002 and 2012","volume":"48","author":"Puhakka","year":"2016","journal-title":"Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e13947","DOI":"10.1111\/tid.13947","article-title":"Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation \u2013 a retrospective single\u2010center study","volume":"24","author":"Ranti","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/j.1600-6143.2010.03225.x","article-title":"Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis","volume":"10","author":"Helanter\u00e4","year":"2010","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13577","DOI":"10.1111\/tid.13577","article-title":"The burden of cytomegalovirus infection remains high in high\u2010risk kidney transplant recipients despite six\u2010month valganciclovir prophylaxis","volume":"23","author":"R\u00e4ih\u00e4","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B18","unstructured":"The act on the secondary use of health and social data\n          \n          \n          2019"},{"key":"B19","volume-title":"Terveyden-Ja Sosiaalihuollon Yksikk\u00f6kustannukset Suomessa Vuonna 2017","author":"M\u00e4klin","year":"2017"},{"key":"B20","volume-title":"A Language and Environment for Statistical Computing","author":"Team","year":"2022"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9429265","article-title":"Drug-induced hematological cytopenia in kidney transplantation and the challenges it poses for kidney transplant physicians","volume":"2018","author":"Khalil","year":"2018","journal-title":"J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/infdis\/jiz194","article-title":"Different impact of rATG induction on CMV infection risk in D+R\u2013 and R+ KTRs","volume":"220","author":"Kaminski","year":"2019","journal-title":"The J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.transproceed.2023.08.021","article-title":"Significant increase in cytomegalovirus (CMV) infection in solid organ transplants associated with increased use of thymoglobulin as induction therapy?","volume":"55","author":"Romao","year":"2023","journal-title":"Transplant Proc"},{"key":"B24","doi-asserted-by":"publisher","first-page":"534681","DOI":"10.3389\/fphar.2020.534681","article-title":"Sex-associated differences in cytomegalovirus prevention: prophylactic strategy is potentially associated with a strong kidney function impairment in female renal transplant patients","volume":"11","author":"Blazquez-Navarro","year":"2020","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.trre.2017.02.003","article-title":"Sex differences in transplantation","volume":"31","author":"Momper","year":"2017","journal-title":"Transplant Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1093\/ckj\/sfad165","article-title":"Leukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up","volume":"16","author":"Schellekens","year":"2023","journal-title":"Clin Kidney J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high\u2010risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.transproceed.2023.11.021","article-title":"Low-dose vs standard-dose valganciclovir for cytomegalovirus prophylaxis after kidney transplantation: a single-center retrospective analysis","volume":"56","author":"Farkas","year":"2024","journal-title":"Transplant Proc"},{"key":"B31","doi-asserted-by":"publisher","first-page":"14342","DOI":"10.3389\/ti.2025.14342","article-title":"Clinical and economic burden associated with anti-cytomegalovirus (CMV) prophylaxis therapies in adult kidney transplant recipients (LECOCYT): an observational study","volume":"38","author":"Kamar","year":"2025","journal-title":"Transpl Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/j.1600-6143.2009.02699.x","article-title":"Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study","volume":"9","author":"Zafrani","year":"2009","journal-title":"Am J Transplant"},{"key":"B33","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1399-0012.2008.00893.x","article-title":"Management of leukopenia in kidney and pancreas transplant recipients","volume":"22","author":"Hartmann","year":"2008","journal-title":"Clin Transplant"},{"key":"B34","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ndt\/gfv378","article-title":"Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the descartes working group and ERBP","volume":"31","author":"Abramowicz","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"B35","doi-asserted-by":"publisher","first-page":"102671","DOI":"10.5500\/wjt.v15.i2.102671","article-title":"Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir","volume":"15","author":"Beyer","year":"2025","journal-title":"World J Transpl"},{"key":"B36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.36469\/001c.125097","article-title":"Healthcare resource utilization associated with leukopenia and neutropenia in kidney transplant recipients receiving valganciclovir in the United States","volume":"12","author":"Li","year":"2025","journal-title":"J Health Econ Outcomes Res"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2026.16893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:10:14Z","timestamp":1790831414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2026.16893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":36,"alternative-id":["10.3389\/ti.2026.16893"],"URL":"https:\/\/doi.org\/10.3389\/ti.2026.16893","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"16893"}}